Role of symmetric dimethylarginine in vascular damage by increasing ROS via store-operated calcium influx in monocytes

Nephrology Dialysis Transplantation

Volumn 24, Issue 5, 2009, Pages 1429-1435

  Schepers, Eva ^a   Glorieux, Griet ^a   Dhondt, Annemieke ^a   Leybaert, Luc ^b   Vanholder, Raymond ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

Calcium; Chronic kidney disease; Guanidines; Leukocytes; Reactive oxygen species

Indexed keywords

CALCIUM; CALCIUM CHANNEL; FORMYLMETHIONYLLEUCYLPHENYLALANINE; GUANIDINE DERIVATIVE; N(G),N(G) DIMETHYLARGININE; REACTIVE OXYGEN METABOLITE; STORE OPERATED CALCIUM CHANNEL; SYMMETRIC DIMETHYLARGININE; UNCLASSIFIED DRUG;

ARTICLE; BLOOD VESSEL INJURY; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CYTOPLASM; EXTRACELLULAR CALCIUM; HUMAN; HUMAN CELL; INFLAMMATION; LEUKOCYTE ACTIVATION; MONOCYTE; PREVALENCE; PRIORITY JOURNAL; RESPIRATORY BURST;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTICOAGULANTS; ARGININE; CALCIUM; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS; CAPTOPRIL; EDETIC ACID; ENZYME INHIBITORS; HUMANS; IMIDAZOLES; MONOCYTES; N-FORMYLMETHIONINE LEUCYL-PHENYLALANINE; REACTIVE OXYGEN SPECIES; RESPIRATORY BURST; THAPSIGARGIN; VASCULAR DISEASES;

EID: 65249184373     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn670     Document Type: Article

References (44)

1. Van Biesen W, De Bacquer D, Verbeke F et al. The glomerular filtration rate in an apparently healthy population and its relation with cardiovascular mortality during 10 years. Eur Heart J 2007; 28: 478-483
2. Vanholder R, Massy Z, Argiles A et al. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant 2005; 20: 1048-1056
3. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32: S112-S119
4. Busch M, Franke S, Muller A et al. Potential cardiovascular risk factors in chronic kidney disease: AGEs, total homocysteine and metabolites, and the C-reactive protein. Kidney Int 2004; 66: 338-347
5. Cheung AK, Sarnak MJ, Yan G et al. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int 2000; 58: 353-362
6. Stenvinkel P, Alvestrand A. Inflammation in end-stage renal disease: sources, consequences, and therapy. Semin Dial 2002; 15: 329-337
7. Vanholder R, Glorieux G, Lameire N. Uraemic toxins and cardiovascular disease. Nephrol Dial Transplant 2003; 18: 463-466
8. Vanholder R, Meert N, Schepers E et al. Uremic toxins: do we know enough to explain uremia? Blood Purif 2008; 26: 77-81
9. Krane V, Krieter DH, Olschewski M et al. Dialyzer membrane characteristics and outcome of patients with type 2 diabetes on maintenance hemodialysis. Am J Kidney Dis 2007; 49: 267-275
10. Locatelli F, Gauly A, Czekalski S et al. The MPO Study: just a European HEMO Study or something very different? Blood Purif 2008; 26: 100-104
11. De Deyn PP, D'Hooge R, Van Bogaert PP et al. Endogenous guanidino compounds as uremic neurotoxins. Kidney Int Suppl 2001; 78: S77-S83
12. Glorieux GL, Dhondt AW, Jacobs P et al. In vitro study ofthe potential role of guanidines in leukocyte functions related to atherogenesis and infection. Kidney Int 2004; 65: 2184-2192
13. Perna AF, Ingrosso D, Satta E et al. Plasma protein aspartyl damage is increased in hemodialysis patients: studies on causes and consequences. J Am Soc Nephrol 2004; 15: 2747-2754
14. Vallance P, Leone A, Calver A et al. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339: 572-575
15. Zoccali C, Bode-Boger S, Mallamaci F et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001; 358: 2113-2117
16. Cooke JP. Asymmetrical dimethylarginine: the Uber marker? Circulation 2004; 109: 1813-1818
17. Kielstein JT, Tsikas D, Fliser D. Effects of asymmetric dimethylargi-nine (ADMA) infusion in humans. Eur J Clin Pharmacol 2006; 62: 39-44
18. Meinitzer A, Seelhorst U, Wellnitz B et al. Asymmetrical dimethy-larginine independently predicts total and cardiovascular mortality in individuals with angiographic coronary artery disease (the Lud-wigshafen Risk and Cardiovascular Health study). Clin Chem 2007; 53: 273-283
19. Bode-Boger SM, Scalera F, Kielstein JT et al. Symmetrical dimethy-larginine: a new combined parameter for renal function and extent of coronary artery disease. J Am Soc Nephrol 2006; 17: 1128-1134
20. Kielstein JT, Salpeter SR, Bode-Boeger SM et al. Symmetric dimethy-larginine (SDMA) as endogenous marker of renal function - a meta-analysis. Nephrol Dial Transplant 2006; 21: 2446-2451
21. Cohen G, Glorieux G, Thornalley P et al. Review on uraemic toxins III: recommendations for handling uraemic retention solutes in vitro towards a standardized approach for research on uraemia. Nephrol Dial Transplant 2007; 22: 3381-3390
22. Vanholder R, De Smet R, Glorieux G et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 2003; 63: 1934-1943
23. do Ceu Monteiro M, Sansonetty F, Goncalves MJ et al. Flow cyto-metric kinetic assay of calcium mobilization in whole blood platelets using Fluo-3 and CD41. Cytometry 1999; 35: 302-310
24. Thastrup O, Dawson AP, Scharff O et al. Thapsigargin, a novel molecular probe for studying intracellular calcium release and storage. 1989. Agents Actions 1994; 43: 187-193
25. Merritt JE, Armstrong WP, Benham CD et al. SK&F 96365, a novel inhibitor of receptor-mediated calcium entry. Biochem J 1990; 271: 515-522
26. Kemmerich B, Pennington JE. Different calcium and oxidative metabolic responses in human blood monocytes during exposure to various agonists. J Leukoc Biol 1988; 43: 125-132
27. Putney JW, Jr. Capacitative calcium entry revisited. Cell Calcium 1990; 11: 611-624
28. 2+ influx. J Vasc Res 1994; 31: 265-270
29. Van Der Giet M, Erinola M, Zidek W et al. Captopril and quinapril reduce reactive oxygen species. Eur J Clin Invest 2002; 32: 732-737
30. RossR.Atherosclerosis-an inflammatory disease. N Engl J Med 1999; 340: 115-126
31. Zalba G, Fortuno A, Diez J. Oxidative stress and atherosclerosis in early chronic kidney disease. Nephrol Dial Transplant 2006; 21: 2686-2690
32. Massry SG, Fadda GZ. Chronic renal failure is a state of cellular calcium toxicity. Am J Kidney Dis 1993; 21: 81-86
33. Koorts AM, Kruger MC, Potgieter CD et al. Intracellular free calcium in the neutrophils of maintenance haemodialysis patients. Clin Physiol Funct Imaging 2002; 22: 285-294
34. 2+ATPase in end-stage renal failure. J Am Soc Nephrol 1998; 9: 1249-1257
35. 2+-ATPase in end-stage renal failure. Kidney Int Suppl 2001; 78: S84-S88
36. 2+ channels in the neuroexcitatory and synergistic effects of putative uremic neurotoxins. Kidney Int 2003; 63: 1764-1775
37. Weiss H, Amberger A, Widschwendter M et al. Inhibition of store-operated calcium entry contributes to the anti-proliferative effect of non-steroidal anti-inflammatory drugs in human colon cancer cells. Int J Cancer 2001; 92: 877-882
38. 2+ entry is associated with the familial Alzheimer's disease presenilin-2 T122R mutation and anticipates the onset of dementia. Neurobiol Dis 2005; 18: 638-648
39. Panaro MA, Acquafredda A, Sisto M et al. Biological role of the N-formyl peptide receptors. Immunopharmacol Immunotoxicol 2006; 28: 103-127
40. Gether U. Uncovering molecular mechanisms involved in activation of G protein-coupled receptors. Endocr Rev 2000; 21: 90-113
41. Eloot S, Torremans A, De Smet R et al. Kinetic behavior of urea is different from that of other water-soluble compounds: the case of the guanidino compounds. Kidney Int 2005; 67: 1566-1575
42. Eloot S, Torremans A, De Smet R et al. Complex compartmental behavior of small water-soluble uremic retention solutes: evaluation by direct measurements in plasma and erythrocytes. Am J Kidney Dis 2007; 50: 279-288
43. Eloot S, Van Biesen W, Dhondt A et al. Impact of hemodialysis duration on the removal of uremic retention solutes. Kidney Int 2007; 73: 765-770
44. Weir MR. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better? Clin Ther 2007; 29: 1803-1824